Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
OBJECTIVE
To test the hypothesis that increased pelvic bone marrow (BM) irradiation is associated with increased hematologic toxicity (HT) in cervical cancer patients undergoing chemoradiotherapy and to develop a normal tissue complication probability (NTCP) model for HT.


METHODS
We tested associations between hematologic nadirs during chemoradiotherapy and the volume of BM receiving≥10 and 20 Gy (V10 and V20) using a previously developed linear regression model. The validation cohort consisted of 44 cervical cancer patients treated with concurrent cisplatin and pelvic radiotherapy. Subsequently, these data were pooled with data from 37 identically treated patients from a previous study, forming a cohort of 81 patients for normal tissue complication probability analysis. Generalized linear modeling was used to test associations between hematologic nadirs and dosimetric parameters, adjusting for body mass index. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints.


RESULTS
In the validation cohort, significant negative correlations were observed between white blood cell count nadir and V10 (regression coefficient (β)=-0.060, p=0.009) and V20 (β=-0.044, p=0.010). In the combined cohort, the (adjusted) β estimates for log (white blood cell) vs. V10 and V20 were as follows: -0.022 (p=0.025) and -0.021 (p=0.002), respectively. Patients with V10≥95% were more likely to experience Grade≥3 leukopenia (68.8% vs. 24.6%, p<0.001) than were patients with V20>76% (57.7% vs. 21.8%, p=0.001).


CONCLUSIONS
These findings support the hypothesis that HT increases with increasing pelvic BM volume irradiated. Efforts to maintain V10<95% and V20<76% may reduce HT.
Rose
Brent S
BS
Department of Radiation Oncology and Center for Advanced Radiotherapy Technologies, University of California, San Diego, La Jolla, CA 92093-0843, USA.
Aydogan
Bulent
B
Liang
Yun
Y
Yeginer
Mete
M
Hasselle
Michael D
MD
Dandekar
Virag
V
Bafana
Rounak
R
Yashar
Catheryn M
CM
Mundt
Arno J
AJ
Roeske
John C
JC
Mell
Loren K
LK
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D015233:Models, Statistical; D009504:Neutrophils / Q000187:drug effects / Q000528:radiation effects; D058958:Organs at Risk / Q000528:radiation effects*; D010388:Pelvis; D010976:Platelet Count; D011336:Probability; D011832:Radiation Injuries / Q000150:complications*; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy*
D000970:Antineoplastic Agents; D006441:Hemoglobin A; D002945:Cisplatin
N Engl J Med. 1999 Apr 15;340(15):1144-53
10202165
Lancet. 2001 Sep 8;358(9284):781-6
11564482
Radiother Oncol. 2005 Oct;77(1):11-7
16024116
Radiology. 1995 Feb;194(2):537-43
7824737
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1504-10
18640499
J Clin Oncol. 2004 Aug 1;22(15):3113-9
15284262
Brachytherapy. 2002;1(4):192-4
15062166
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88
7635767
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7
8436516
Mol Imaging Biol. 2007 Nov-Dec;9(6):361-5
17899296
Cancer. 1973 Sep;32(3):699-711
4726969
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):118-25
17869451
Gynecol Oncol. 2005 Nov;99(2):334-8
16023181
J Clin Oncol. 1999 May;17(5):1339-48
10334517
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61
16168830
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
7713792
Gynecol Oncol. 2004 Mar;92(3):801-5
14984944
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1431-7
17996390
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65
16757127
Gynecol Oncol. 2001 Apr;81(1):88-91
11277656
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39
7713791
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1388-96
12459361
Radiother Oncol. 1984 Oct;2(3):215-25
6528057
J Clin Oncol. 2005 Jul 20;23(21):4626-33
15911865
Am J Clin Pathol. 1965 Apr;43:326-31
14275849
J Clin Oncol. 2000 Apr;18(8):1606-13
10764420
N Engl J Med. 1999 Apr 15;340(15):1154-61
10202166
Radiology. 1988 Sep;168(3):679-93
3043546
Phys Med Biol. 1961 Jan;5:255-8
13726497
J Clin Oncol. 2002 Feb 15;20(4):966-72
11844818
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):817-23
15708261
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1043-7
20471182
Cancer. 1978 Sep;42(3):1057-65
100197
N Engl J Med. 1999 Apr 15;340(15):1137-43
10202164
Gynecol Oncol. 2009 Jan;112(1):85-9
18977518
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):140-6
18922646
J Clin Oncol. 2004 Mar 1;22(5):872-80
14990643